Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. junior Avg
|
New words:
advisory, bore, broker, coupled, exfiltrated, external, GMP, hypothetical, inaccessible, IndexADMA, noteholder, original, prudent, restore, restored, root, subside, theoretically, unfavorable, unfavorably, week
Removed:
Caligan, goal, NWQ, opened, professional, Pvt, track
Filing tables
Filing exhibits
Related press release
Associated ADMA transcripts
ADMA similar filings
Filing view
External links
Exhibit 32.1
CERTIFICATION OF THE PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of ADMA Biologics, Inc., a Delaware corporation (the “Company”), on Form 10-Q for the quarter ended June 30, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Adam S. Grossman, President and Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:
1. | The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and |
2. | The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
Date: August 9, 2023 | By: | /s/ Adam S. Grossman |
Name: | Adam S. Grossman | |
Title: | President and Chief Executive Officer (Principal Executive Officer) |